A Pilot Study of Allogeneic Lymphocyte Transfer in HIV Infection
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring T-Lymphocytes, Acquired Immunodeficiency Syndrome, Transplantation, Homologous, Immunotherapy, Adoptive
Eligibility Criteria
Inclusion Criteria Concurrent Medication: Required: Stable antiretroviral therapy. Allowed: Maintenance therapy for a controlled opportunistic infection. Patients must have: HIV infection. CD4 count 50-200 cells/mm3. No ongoing major opportunistic infections. Been on stable antiretroviral therapy for the past 2 months. Tonsils present. Life expectancy greater than 6 months. An HLA-single haplotype matched, single haplotype mismatched parent, sibling, or adult offspring who is ABO, Rh compatible to serve as an HIV-negative lymphocyte donor. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Lymphoma or other malignancy requiring chemotherapy. Bleeding disorder that would preclude a tonsillar biopsy. Antibody on donor/recipient lymphocyte reactive antibody assay. Donors with the following symptoms or conditions are excluded: Medical condition that would endanger health of donor or recipient. Failure to meet established donor standards on blood screening tests. CMV seropositivity if the patient (recipient) is CMV seronegative. Pregnancy. Concurrent Medication: Excluded: GM-CSF or G-CSF. Any investigational drug. Immunomodulators (such as interferon, steroids, topical corticosteroids, thalidomide, pentoxifylline, IL-2). Nonsteroidal anti-inflammatory drugs. Aspirin. Prior Treatment: Excluded: Blood transfusion within the past 2 months. Required: Stable antiretroviral therapy for at least 2 months prior to study entry. Active substance abuse.
Sites / Locations
- Univ Hosp of Cleveland / Case Western Reserve Univ